Huahai Pharmaceuticals Memantine Hydrochloride Tablets Obtained Drug Registration Certificate

On August 31, Huahai Pharmaceutical issued an announcement stating that the company had recently received a "drug registration certificate" for memantine hydrochloride tablets approved and issued by the National Medical Products Administration for the treatment of moderate to severe Alzheimer's dementia

In November 2019, the company's application for drug registration of memantine hydrochloride tablets submitted to the Drug Evaluation Center of the National Medical Products Administration (hereinafter referred to as "the Evaluation Center of the National Medical Products Administration") was accepted (acceptance number: CYHS1900807); recently, The company received the "Drug Registration Certificate" for memantine hydrochloride tablets approved and issued by the State Food and Drug Administration

Memantine hydrochloride tablets are mainly used to treat moderate to severe Alzheimer's dementia

Up to now, the company has invested approximately RMB 3,318,200 in research and development projects for memantine hydrochloride tablets

According to relevant national policies, the company's memantine hydrochloride tablets are approved for production according to category 4 chemicals, which can be regarded as passing the consistency evaluation